Literature DB >> 23721889

Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings.

Sarah Laraway1, Catherine Breen, Jean Mercer, Simon Jones, James E Wraith.   

Abstract

Enzyme replacement therapy is widely used as treatment for mucopolysaccharidosis I (MPS I), and there is evidence that this produces improvement in certain clinical domains. There does appear to be variation in the response of clinical features to treatment once these are established. In a reported sibling pair, when enzyme replacement therapy was commenced pre-symptomatically in the younger child, the natural history of the condition appeared to be affected. We present data from three siblings treated with enzyme replacement therapy at different ages which supports this finding.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23721889     DOI: 10.1016/j.ymgme.2013.04.023

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  19 in total

1.  Long-term nonsense suppression therapy moderates MPS I-H disease progression.

Authors:  Gwen Gunn; Yanying Dai; Ming Du; Valery Belakhov; Jeyakumar Kandasamy; Trenton R Schoeb; Timor Baasov; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2013-12-17       Impact factor: 4.797

2.  Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.

Authors:  Joseph A Chiaro; Patricia O'Donnell; Eileen M Shore; Neil R Malhotra; Katherine P Ponder; Mark E Haskins; Lachlan J Smith
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

3.  The diagnostic journey of patients with mucopolysaccharidosis I: A real-world survey of patient and physician experiences.

Authors:  Stefano Bruni; Christine Lavery; Alexander Broomfield
Journal:  Mol Genet Metab Rep       Date:  2016-08-02

4.  12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment.

Authors:  Orazio Gabrielli; Lorne A Clarke; Anna Ficcadenti; Lucia Santoro; Lucia Zampini; Nicola Volpi; Giovanni V Coppa
Journal:  BMC Med Genet       Date:  2016-03-10       Impact factor: 2.103

5.  Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications.

Authors:  Gé-Ann Kuiper; Olga L M Meijer; Eveline J Langereis; Frits A Wijburg
Journal:  Orphanet J Rare Dis       Date:  2018-01-08       Impact factor: 4.123

6.  Residual glycosaminoglycan accumulation in mitral and aortic valves of a patient with attenuated MPS I (Scheie syndrome) after 6 years of enzyme replacement therapy: Implications for early diagnosis and therapy.

Authors:  Yohei Sato; Masako Fujiwara; Hiroshi Kobayashi; Michio Yoshitake; Kazuhiro Hashimoto; Yuji Oto; Hiroyuki Ida
Journal:  Mol Genet Metab Rep       Date:  2015-11-08

7.  Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases.

Authors:  Kim M Keeling
Journal:  Diseases       Date:  2016-10-19

8.  Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships.

Authors:  Nouriya A Al-Sannaa; Luisa Bay; Deborah S Barbouth; Youssef Benhayoun; Cyril Goizet; Norberto Guelbert; Simon A Jones; Sandra Obikawa Kyosen; Ana Maria Martins; Chanika Phornphutkul; Celia Reig; Rebecca Pleat; Shari Fallet; Iva Ivanovska Holder
Journal:  Orphanet J Rare Dis       Date:  2015-10-07       Impact factor: 4.123

9.  Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.

Authors:  Dafne Dain Gandelman Horovitz; Angelina X Acosta; Roberto Giugliani; Anna Hlavatá; Katarína Hlavatá; Michel C Tchan; Anneliese Lopes Barth; Laercio Cardoso; Emília Katiane Embiruçu de Araújo Leão; Ana Carolina Esposito; Sandra Obikawa Kyosen; Carolina Fischinger Moura De Souza; Ana Maria Martins
Journal:  Orphanet J Rare Dis       Date:  2016-04-29       Impact factor: 4.123

10.  Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome.

Authors:  Julie B Eisengart; Jeanine Jarnes; Alia Ahmed; Igor Nestrasil; Richard Ziegler; Kathleen Delaney; Elsa Shapiro; Chester Whitley
Journal:  Mol Genet Metab Rep       Date:  2017-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.